The insider sales are small relative to market cap and likely routine profit-taking or liquidity-driven, especially given the positive earnings catalyst. However, the cluster includes the CEO and COO selling immediately after a PRV-driven earnings beat—monitor for any additional insider sales in the next 30 days; a continuation would increase bearish signal. The stock's 55% analyst bullish consensus and $283.7M cash runway provide a fundamental floor, but the lack of insider buying at these depressed levels is a subtle negative.
Price Chart
Executive Summary
Three Rocket Pharmaceuticals insiders, including the CEO and COO, sold a total of $154K in open-market sales over a 7-day window following the company's Q2 2026 earnings release. The earnings report showed a GAAP net income of $123.2M driven by a $178.2M PRV sale, but the insider selling cluster—particularly the COO's $128K sale—suggests insiders are taking profits or lack conviction in the stock's near-term upside at the current ~$3.50 price level. The total dollar value is 0.04% of the $381M market cap, which is trivial and likely routine, but the cluster's proximity to positive earnings and the CEO's participation warrants attention.
Key Financial Metrics
Key Facts
- CEO Shah Gaurav sold 2,837 shares at $3.381 for ~$10K on 2026-08-13.
- COO Stevens Christopher James sold 36,658 shares at $3.499 for ~$128K on 2026-08-11.
- General Counsel Wilson Martin sold 3,493 shares at $3.381 for ~$12K on 2026-08-13.
- Total insider sales of $154K represent 0.04% of RCKT's $381M market cap—trivial by proportionality standards.
- Sales occurred 3-7 days after Q2 2026 earnings showing a $123.2M GAAP net income, driven by a $178.2M PRV sale.
- The company ended Q2 2026 with $283.7M cash, extending runway into Q2 2028.
Financial Impact
Total insider sales of $154K, or 0.04% of market cap, are immaterial to the company's financial position.
Risk Factors
- Insider selling cluster may signal lack of confidence in near-term stock appreciation despite positive earnings.
- The $178.2M PRV gain is non-recurring; core operating loss of $46.9M in Q2 2026 still indicates cash burn.
- Stock price at ~$3.50 is near 52-week lows; further insider sales could exacerbate selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RCKT-1787004115933 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $3.41 $3.35 | ▼ −1.76% | ▼ −3.89% | $2.56 (−24.93%) |
Aug 20, 2026 6w ago | Insider Cluster | $3.48 $3.62 | ▲ +4.02% | ▲ +2.91% | $2.56 (−26.44%) |
Aug 17, 2026 6w ago | Insider Cluster | $3.34 $3.78 | ▲ +13.17% | ▲ +13.37% | $2.56 (−23.35%) |
Aug 13, 2026 7w ago | Insider Cluster | $3.34 $3.48 | ▲ +4.04% | ▲ +6.01% | $2.56 (−23.35%) |
Aug 10, 2026 7w ago | 8-K | $3.50 $3.34 | ▼ −4.57% | ▼ −4.17% | $2.56 (−26.86%) |
Aug 3, 2026 8w ago | 8-K | $3.41 $3.64 | ▲ +6.74% | ▲ +4.72% | $2.56 (−24.93%) |
Jun 30, 2026 13w ago | 8-K | $3.52 $4.07 | ▲ +15.63% | ▲ +15.36% | $2.56 (−27.27%) |
Jun 12, 2026 16w ago | 8-K | $2.75 $3.35 | ▲ +21.82% | ▲ +21.15% | $2.56 (−6.91%) |
May 26, 2026 18w ago | Insider Cluster | $2.99 $2.92 | ▼ −2.34% | ▼ −2.81% | $2.56 (−14.38%) |
May 7, 2026 21w ago | Insider Cluster | $3.25 $2.96 | ▼ −8.92% | ▼ −9.89% | $2.56 (−21.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access